Compare TOI & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOI | TECX |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United States | United States |
| Employees | N/A | 51 |
| Industry | Medical/Nursing Services | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.6M | 393.0M |
| IPO Year | N/A | N/A |
| Metric | TOI | TECX |
|---|---|---|
| Price | $2.76 | $34.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $6.00 | ★ $80.40 |
| AVG Volume (30 Days) | ★ 1.3M | 551.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.51 | N/A |
| Revenue Next Year | $27.09 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $13.70 |
| 52 Week High | $4.88 | $35.99 |
| Indicator | TOI | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 74.75 |
| Support Level | $2.37 | $16.83 |
| Resistance Level | $2.97 | N/A |
| Average True Range (ATR) | 0.20 | 2.56 |
| MACD | 0.03 | 1.26 |
| Stochastic Oscillator | 51.20 | 93.12 |
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.